Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL-2 binding (Q36353604)

From Wikidata

Jump to navigation Jump to search

scientific article published on October 1, 1990

Language	Label	Description	Also known as
English	Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL-2 binding	scientific article published on October 1, 1990

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL-2 binding (English)

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

1 reference

10.1084/JEM.172.4.1101

https://api.crossref.org/works/10.1084/JEM.172.4.1101

2 November 2022

author name string

S. D. Voss

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1698909

2 November 2022

R. J. Robb

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1698909

2 November 2022

G. Weil-Hillman

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1698909

2 November 2022

J. A. Hank

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1698909

2 November 2022

K. Sugamura

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1698909

2 November 2022

M. Tsudo

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1698909

2 November 2022

P. M. Sondel

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1698909

2 November 2022

language of work or name

0 references

publication date

1 October 1990

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

full work available at URL

https://europepmc.org/articles/PMC2188601

online access status

content deliverer

Europe PubMed Central

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1698909

2 November 2022

https://europepmc.org/articles/PMC2188601?pdf=render

Portable Document Format

online access status

content deliverer

Europe PubMed Central

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1698909

2 November 2022

http://rupress.org/jem/article-pdf/172/4/1101/1100844/1101.pdf

Portable Document Format

1 reference

10.1084/JEM.172.4.1101

https://api.crossref.org/works/10.1084/JEM.172.4.1101

2 November 2022

Journal of Experimental Medicine

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

172

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

4

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

1101-1114

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Characterization of the human receptor for T-cell growth factor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

30 September 2017

Direct demonstration of the identity of T cell growth factor binding protein and the Tac antigen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

30 September 2017

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

30 September 2017

Low and high affinity cellular receptors for interleukin 2. Implications for the level of Tac antigen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

30 September 2017

Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

30 September 2017

The construction and characterization of a biologically active recombinant IL-2 containing a lysine-rich C-terminal extension.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

30 September 2017

Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

30 September 2017

Structure-function relationships for the interleukin 2 receptor: location of ligand and antibody binding sites on the Tac receptor chain by mutational analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

30 September 2017

The interleukin 2 receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

30 September 2017

The interleukin 2 receptor. Functional consequences of its bimolecular structure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

30 September 2017

The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

30 September 2017

Interleukin 2 high-affinity receptor expression requires two distinct binding proteins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

30 September 2017

Immunotherapy of cancer using interleukin 2: current status and future prospects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

30 September 2017

Interleukin-2 in cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

30 September 2017

Interleukin 2 binding molecule distinct from the Tac protein: analysis of its role in formation of high-affinity receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

30 September 2017

Internalization of interleukin 2 is mediated by the beta chain of the high-affinity interleukin 2 receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

30 September 2017

Structure and function of human and murine receptors for IgG.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

30 September 2017

Novel interleukin 2 (IL-2) receptor appears to mediate IL-2-induced activation of natural killer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

30 September 2017

Interleukin-2 receptor beta chain gene: generation of three receptor forms by cloned human alpha and beta chain cDNA's

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

30 September 2017

The multi-subunit interleukin-2 receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

30 September 2017

Characterization of the interleukin 2 receptor beta chain using three distinct monoclonal antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

30 September 2017

Flow cytometric resonance energy transfer measurements support the association of a 95-kDa peptide termed T27 with the 55-kDa Tac peptide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

30 September 2017

Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

30 September 2017

Response of resting human peripheral blood natural killer cells to interleukin 2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

29 June 2018

Molecular cloning of cDNA encoding human interleukin-2 receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

29 June 2018

Molecular cloning and expression of cDNAs for the human interleukin-2 receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

29 June 2018

Co-internalization of the p55 and p70 subunits of the high-affinity human interleukin 2 receptor. Evidence for a stable ternary receptor complex

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

29 June 2018

Direct identification of the murine IL-2 receptor p55-p75 heterodimer in the absence of IL-2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

29 June 2018

Release of soluble interleukin-2 receptors (Tac peptide) in vivo during human immune responses to tuberculin.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

29 June 2018

The mouse high affinity IL 2 receptor complex. I. Evidence for a third molecule, the putative gamma-chain, associated with the alpha- and/or beta-chain of the receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

29 June 2018

Contrasting interleukin 2 binding properties of the alpha (p55) and beta (p70) protein subunits of the human high-affinity interleukin 2 receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

29 June 2018

Novel interleukin-2 receptor subunit detected by cross-linking under high-affinity conditions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

29 June 2018

Direct activation of human resting T cells by IL 2: the role of an IL 2 receptor distinct from the Tac protein.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

29 June 2018

Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

29 June 2018

Activation of natural killer cells via the p75 interleukin 2 receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

29 June 2018

Monoclonal antibody defining a molecule possibly identical to the p75 subunit of interleukin 2 receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

29 June 2018

Reconstitution of a functional IL-2 receptor by the beta-chain cDNA. A newly acquired receptor transduces negative signal

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

29 June 2018

TCGF (IL 2)-receptor inducing factor(s). I. Regulation of IL 2 receptor on a natural killer-like cell line (YT cells).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

29 June 2018

Activation of peripheral blood T cells via the p75 interleukin 2 receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

29 June 2018

Membrane anchoring and spontaneous release of CD16 (FcR III) by natural killer cells and granulocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

29 June 2018

Depressed in vitro T cell responses concomitant with augmented interleukin-2 responses by lymphocytes from cancer patients following in vivo treatment with interleukin-2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

29 June 2018

Constitutive expression of high affinity interleukin 2 receptors on human CD16-natural killer cells in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

29 June 2018

Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188601

29 June 2018

Plasma interleukin 2 receptor levels in renal allograft recipients

1 reference

https://pubmed.ncbi.nlm.nih.gov/1698909

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A second human interleukin-2 binding protein that may be a component of high-affinity interleukin-2 receptors

1 reference

https://pubmed.ncbi.nlm.nih.gov/1698909

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens

1 reference

https://pubmed.ncbi.nlm.nih.gov/1698909

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differential expression of the IL-2 receptor subunits, p55 and p75 on various populations of primary peripheral blood mononuclear cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/1698909

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

IL-2 receptors on circulating natural killer cells and T lymphocytes. Similarity in number and affinity but difference in transmission of the proliferation signal

1 reference

https://pubmed.ncbi.nlm.nih.gov/1698909

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation

1 reference

https://pubmed.ncbi.nlm.nih.gov/1698909

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/1698909

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://pubmed.ncbi.nlm.nih.gov/1698909

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype

1 reference

https://pubmed.ncbi.nlm.nih.gov/1698909

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of natural and recombinant IL 2 on regulation of IFN gamma production and natural killer activity: lack of involvement of the Tac antigen for these immunoregulatory effects

1 reference

https://pubmed.ncbi.nlm.nih.gov/1698909

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens

1 reference

https://pubmed.ncbi.nlm.nih.gov/1698909

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor

1 reference

https://pubmed.ncbi.nlm.nih.gov/1698909

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings

1 reference

https://pubmed.ncbi.nlm.nih.gov/1698909

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/1698909

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration

1 reference

https://pubmed.ncbi.nlm.nih.gov/1698909

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunoglobulin G Fc receptors of human leukocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/1698909

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Protein phosphorylation mediated by IL-2/IL-2 receptor beta-chain interaction

1 reference

https://pubmed.ncbi.nlm.nih.gov/1698909

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1084/JEM.172.4.1101

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36353604&oldid=1764603726"